A Combined Single- and Multiple-dose, Open-label, Randomized, 6 x 3 Crossover Study to Investigate the Relative Bioavailability, Safety and Tolerability of Elinzanetant (BAY 3427080) in Healthy Female Participants
Latest Information Update: 25 Nov 2025
At a glance
- Drugs Elinzanetant (Primary)
- Indications Sleep disorders; Vasomotor symptoms
- Focus Pharmacokinetics
- Sponsors Bayer
Most Recent Events
- 25 Nov 2025 New trial record